CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
The drug will be marketed under the brand name Molnaflu
Zeebon is the largest diagnostics services provider in North-Eastern states
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company has developed the API in house at its R&D center in Hyderabad
Flattish volume growth and subdued new launches were key factors for last month
Dr. Reddy's valsartan tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Subscribe To Our Newsletter & Stay Updated
